Project Grant R01HL175155
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$780K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to characterize the disease progression and molecular mechanisms of VEXAS syndrome, a newly identified severe autoinflammatory and hematologic disorder caused by somatic mutations in the UBA1 gene. The $159,512 award to New York University School of Medicine will establish mouse models to recapitulate the UBA1 mutations and...
This $198,170 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) will support research to investigate the functional role of a specific protein domain (degron) in the ASXL1 gene and how it impacts hematopoiesis and hematological disorders. The research aims to characterize the ASXL1 degron and identify the E3 ubiquitin ligase that regulates its degradation, as well as establish the relevance of...
The federal Project Grant award F31HL178296, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research focused on understanding how co-occurring mutations in the DDX41 and CUX1 genes contribute to the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The $161,922 award, with a performance period from July 2025 to March 2028, will enable the researcher to use zebrafish and...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award of $889,998 under CFDA 93.837 (Cardiovascular Diseases Research) aims to develop a novel alpha-retroviral vector-based technology platform for in vivo and ex vivo delivery of genetic therapies to hematopoietic stem cells (HSCs). The key objectives are to: (I) develop integrating vectors to deliver a curative transgene to HSCs in vivo to treat X-linked severe combined immunodeficiency (X-SCID); (II) engineer virus-like...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $736,574 to the Icahn School of Medicine at Mount Sinai to investigate the role of the RNA-binding protein DDX3X in heart development and disease. The award aims to uncover the direct and functionally relevant targets of DDX3X, determine the cellular phenotype of DDX3X-deficient embryos, and elucidate genotype-phenotype correlations in...
This Project Grant award, valued at $1,419,308 and spanning from September 2024 to August 2025, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to investigate the mechanisms linking persistent DNA damage to the upregulation of the NLRP12 gene, and the functional implications of this link in aging hematopoiesis. The research aims to establish a novel interplay between persistent DNA...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to gain a mechanistic understanding of erythroid progenitor self-renewal, both in vitro and in vivo. The goal is to expand erythroid progenitors to maintain steady-state erythropoiesis and respond to acute anemic or hypoxic stress. The research, conducted by the University of Rochester, focuses on how the chromatin modulators BMI1 and RING1B...
The $814,209 federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel nanoparticle-based gene therapy approach for in vivo hematopoietic stem cell (HSC) modification. The project aims to optimize nanoparticle formulations that can deliver next-generation gene-editing agents and target the HSC-enriched cell population identified in the researchers' prior...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $581,493 to the University of Rochester to conduct research into the molecular mechanisms underlying valvular heart disease (VHD). The project aims to determine how the protein kinase D3 (PKD3) regulates endothelial-mesenchymal transition (EndMT) and heart valve development, function, and pathological changes. The research seeks to...
This $300,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Gigamune, Inc. to develop an in vivo gene therapy approach for treating sickle cell disease. The project aims to assess the efficiency and specificity of a novel lentiviral vector platform for delivering CRISPR/Cas9 gene editing machinery to hematopoietic stem cells to knock out the BCL11A enhancer, with the goal of...